//www.koonmotors.com/news/health_medicine/amyotrophic_lateral_sclerosis/ Latest research news on amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, including experimental treatments. en-us Mon, 28 Aug 2023 19:46:41 EDT Mon, 28 Aug 2023 19:46:41 EDT 60 //www.koonmotors.com/images/scidaily-logo-rss.png//www.koonmotors.com/news/health_medicine/amyotrophic_lateral_sclerosis/ For more science news, visit ScienceDaily. //www.koonmotors.com/releases/2023/08/230818004425.htm Amyotrophic lateral sclerosis (ALS) is a widespread neurodegenerative disease caused by the loss of neurons that control movement. Although abnormal accumulation of proteins called TDP-43 accompanies ALS, its role in disease progression is not well understood. Recently, using novel mouse models of ALS, researchers have identified the neurological spreading patterns through which TDP-43 perpetuates the degeneration of the movement-related neural circuitry. Fri, 18 Aug 2023 00:44:25 EDT //www.koonmotors.com/releases/2023/08/230818004425.htm //www.koonmotors.com/releases/2023/07/230721113208.htm Researchers have shown that hundreds of proteins and mRNA molecules are found in the wrong place in nerve cells affected by Motor Neuron Disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS). Fri, 21 Jul 2023 11:32:08 EDT //www.koonmotors.com/releases/2023/07/230721113208.htm //www.koonmotors.com/releases/2023/06/230602115106.htm 肌萎缩性脊髓侧索硬化症(ALS),也被称为Lou Gehrig's disease, is a fatal motor neuron disease that causes people to gradually lose control of their muscles. There is no cure, and current treatments focus on reducing symptoms and providing supportive care. Researchers now show in an early clinical trial that the Parkinson's disease drug ropinirole is safe to use in ALS patients and delayed disease progression by 27.9 weeks on average. Fri, 02 Jun 2023 11:51:06 EDT //www.koonmotors.com/releases/2023/06/230602115106.htm //www.koonmotors.com/releases/2023/03/230316154104.htm Researchers use a DNA designer drug to restore key protein levels in motor neurons, delaying paralysis in a mouse model of ALS. Thu, 16 Mar 2023 15:41:04 EDT //www.koonmotors.com/releases/2023/03/230316154104.htm //www.koonmotors.com/releases/2023/03/230310103513.htm Researchers have identified a new therapeutic target that could lead to more effective treatment of glaucoma. Fri, 10 Mar 2023 10:35:13 EST //www.koonmotors.com/releases/2023/03/230310103513.htm //www.koonmotors.com/releases/2023/02/230227132537.htm Scientists know that TDP-43, which helps regulate processing of RNA, may be responsible for the death of nerve cells in ALS and frontotemporal dementia. And a study suggests that a common modification to RNA, a methylation event known as m6A, plays a pivotal role in TDP-43-related neurodegeneration in ALS. Through sequencing analysis, investigators showed that methylation strongly influences the binding of TDP-43 to its RNA targets. They also observed highly abundant RNA methylation in the end-stage tissues of patients with ALS. Mon, 27 Feb 2023 13:25:37 EST //www.koonmotors.com/releases/2023/02/230227132537.htm //www.koonmotors.com/releases/2023/02/230202081819.htm A new microscopic technique allows for the real-time study of RNA G-quadruplexes in living cells, with implications for the fight against amyotrophic lateral sclerosis. Thu, 02 Feb 2023 08:18:19 EST //www.koonmotors.com/releases/2023/02/230202081819.htm //www.koonmotors.com/releases/2022/12/221201082201.htm Scientists have taken a key step toward better understanding neurodegenerative diseases by using a suite of biophysical techniques to learn more about a motor protein whose malfunction is associated with many disorders. Thu, 01 Dec 2022 08:22:01 EST //www.koonmotors.com/releases/2022/12/221201082201.htm //www.koonmotors.com/releases/2022/09/220921210027.htm 一个国际罕见的3期临床试验, inherited form of ALS showed that an investigational drug, known as tofersen, reduced molecular signs of disease, but at six months did not improve motor control and muscle strength. However, the researchers found evidence that longer-term use of the drug may help stabilize muscle strength and control. Wed, 21 Sep 2022 21:00:27 EDT //www.koonmotors.com/releases/2022/09/220921210027.htm //www.koonmotors.com/releases/2022/09/220921210024.htm Scientists believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care, after the results of a Phase 3 clinical trial showed significant physical benefits for patients after 12 months. Wed, 21 Sep 2022 21:00:24 EDT //www.koonmotors.com/releases/2022/09/220921210024.htm //www.koonmotors.com/releases/2022/08/220830093242.htm Researchers have developed the first mouse model for a mitochondrial tRNALeu mutation, showing that the associated metabolic disorder results from faulty RNA processing. Tue, 30 Aug 2022 09:32:42 EDT //www.koonmotors.com/releases/2022/08/220830093242.htm //www.koonmotors.com/releases/2022/06/220622154935.htm The immune system may play a fundamental role along with the central nervous system in amyotrophic lateral sclerosis (ALS), also known as 'Lou Gehrig's disease,' researchers report. Wed, 22 Jun 2022 15:49:35 EDT //www.koonmotors.com/releases/2022/06/220622154935.htm //www.koonmotors.com/releases/2022/06/220621184506.htm Amyotrophic lateral sclerosis (ALS) is a progressive disease of the nervous system. It affects nerve cells in the brain and spinal cord called motor neurons. Motor neurons control muscle movement and ALS causes them to deteriorate and eventually die. The motor neurons lose the ability to send messages to the muscles in the body, affecting voluntary muscle movements. There have been recent advances in treating ALS, but current treatments can only slow disease progression. That is why it is important to diagnose ALS as early as possible. Tue, 21 Jun 2022 18:45:06 EDT //www.koonmotors.com/releases/2022/06/220621184506.htm //www.koonmotors.com/releases/2022/05/220518113848.htm New preclinical research on the experimental drug, NU-9, to treat ALS shows it is more effective than existing FDA-approved drugs for the disease. More importantly, NU-9 has an enhanced effect when given in combination with those drugs. Wed, 18 May 2022 11:38:48 EDT //www.koonmotors.com/releases/2022/05/220518113848.htm //www.koonmotors.com/releases/2022/03/220329090727.htm Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that affects as many as 30,000 people in the United States, with 5,000 new cases diagnosed each year. It weakens muscles over time, impacting physical function and ultimately leading to death. There is no single cause for the disease and no known cure. However, researchers have found a possible window of opportunity during ALS treatment to target astrocyte abnormalities. Tue, 29 Mar 2022 09:07:27 EDT //www.koonmotors.com/releases/2022/03/220329090727.htm //www.koonmotors.com/releases/2022/02/220228161621.htm Researchers from two independent research teams have discovered how the mislocalization of a protein, known as TDP-43, alters the genetic instructions for UNC13A, providing a possible therapeutic target that could also have implications in treating amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other forms of dementia. ALS and FTD are two neurodegenerative disorders in which many cases are linked by mislocalization of TDP-43, where instead of being primarily located in the nucleus of the cell where genes are activated, it forms aggregates outside the nucleus in multiple neurodegenerative diseases. Rare mutations in the TDP-43 gene are known to cause ALS, but almost all cases of ALS show mislocalization of TDP-43. Mon, 28 Feb 2022 16:16:21 EST //www.koonmotors.com/releases/2022/02/220228161621.htm //www.koonmotors.com/releases/2022/02/220223111310.htm A pioneering new study has revealed, for the first time, why a common genetic variant worsens disease outcomes for people with the devastating adult-onset neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Wed, 23 Feb 2022 11:13:10 EST //www.koonmotors.com/releases/2022/02/220223111310.htm //www.koonmotors.com/releases/2022/01/220126144226.htm In a new meta-analysis of available ALS literature, researchers explore environmental influences potentially linked ALS disease, using rigorous quantitative methods. The study also examines the distribution of ALS over space and time, correlating geographic data with exposure risks and lifestyle or occupational hazards. Wed, 26 Jan 2022 14:42:26 EST //www.koonmotors.com/releases/2022/01/220126144226.htm //www.koonmotors.com/releases/2022/01/220118203557.htm Scientists have revealed harmful changes in supporting cells, called astrocytes, in amyotrophic lateral sclerosis (ALS). Tue, 18 Jan 2022 20:35:57 EST //www.koonmotors.com/releases/2022/01/220118203557.htm //www.koonmotors.com/releases/2021/12/211208123354.htm Scientists have determined the structure of the molecule associated with amyotrophic lateral sclerosis (ALS) and multiple other neurodegenerative diseases. The researchers say this discovery could enable targeted development of new medical interventions and diagnostic tests. Wed, 08 Dec 2021 12:33:54 EST //www.koonmotors.com/releases/2021/12/211208123354.htm //www.koonmotors.com/releases/2021/12/211202191146.htm The brain is indeed a target for treating ALS (amyotrophic lateral sclerosis), scientists have discovered. This flips a long-standing belief the disease starts in the spinal motor neurons and any therapy would need to target the spine as the key focus. The new study shows the brain degenerates early in ALS, sends warning signals and shows defects very early in the disease. Degeneration of brain motor neurons is not merely a byproduct of the spinal motor neuron degeneration, as had been previously thought. Thu, 02 Dec 2021 19:11:46 EST //www.koonmotors.com/releases/2021/12/211202191146.htm //www.koonmotors.com/releases/2021/11/211119155535.htm Riluzole, a drug approved to treat amyotrophic lateral sclerosis (ALS), a disease affecting nerve cells controlling movement, could slow the gradual loss of a particular brain cell that occurs in Niemann-Pick disease type C1 (NPC1), a rare genetic disorder affecting children and adolescents, suggests a study in mice. Fri, 19 Nov 2021 15:55:35 EST //www.koonmotors.com/releases/2021/11/211119155535.htm //www.koonmotors.com/releases/2021/11/211115123558.htm Investigators found elevated levels of tau and a phosphorylated form of the tau protein in brain tissue from deceased people who had amyotrophic lateral sclerosis (ALS) and carried a mutation in the C9orf72 gene. The team also identified new genetic mutations in the tau gene that may exacerbate ALS onset or progression. Tau in the cerebrospinal fluid may be a viable biomarker for ALS because levels correlate with disease progression. Mon, 15 Nov 2021 12:35:58 EST //www.koonmotors.com/releases/2021/11/211115123558.htm //www.koonmotors.com/releases/2021/11/211110131501.htm Investigators have found that an abnormal form of the tau protein is present in brain tissue from deceased patients who had amyotrophic lateral sclerosis (ALS). Cells that were grown in contact with deceased ALS patients' brain tissue that contained abnormal tau exhibited fragmentation of mitochondria and showed signs of oxidative stress. Reducing tau reversed these effects, lowering mitochondrial fragmentation and decreasing oxidative stress. Wed, 10 Nov 2021 13:15:01 EST //www.koonmotors.com/releases/2021/11/211110131501.htm //www.koonmotors.com/releases/2021/06/210630091350.htm Amyotrophic lateral sclerosis, or ALS, attacks nerve cells known as motor neurons in the brain and spinal cord, gradually leading to paralysis. The loss of function of an important gene, C9orf72, may affect communication between motor neurons and muscles in people with this disease. Wed, 30 Jun 2021 09:13:50 EDT //www.koonmotors.com/releases/2021/06/210630091350.htm //www.koonmotors.com/releases/2021/06/210616143159.htm Researchers find an increase in inflammatory molecules in serum and cerebrospinal fluid of C90RF72 patients, informing future anti-inflammatory therapies. Wed, 16 Jun 2021 14:31:59 EDT //www.koonmotors.com/releases/2021/06/210616143159.htm //www.koonmotors.com/releases/2021/06/210608113241.htm Researchers now report a high-throughput target and drug discovery platform using motor neurons made from ALS patients. Using the platform, they confirmed two known targets and identified an existing class of drugs -- agonists to the dopamine D2 receptor -- as potential novel treatments. Tue, 08 Jun 2021 11:32:41 EDT //www.koonmotors.com/releases/2021/06/210608113241.htm //www.koonmotors.com/releases/2021/03/210312084731.htm Scientists have determined the structure of protein 'fibrils' linked to Lou Gehrig's disease and other neurodegenerative disorders -- findings that provide clues to how toxic proteins clump and spread between nerve cells in the brain. Fri, 12 Mar 2021 08:47:31 EST //www.koonmotors.com/releases/2021/03/210312084731.htm //www.koonmotors.com/releases/2021/02/210223110414.htm Scientists have identified the first compound that eliminates the ongoing degeneration of upper motor neurons that become diseased and are a key contributor to ALS (amyotrophic lateral sclerosis), a swift and fatal neurodegenerative disease that paralyzes its victims. In ALS, movement-initiating nerve cells in the brain and muscle-controlling nerve cells in the spinal cord die. After administering the new compound,, the diseased brain neurons stopped degenerating so much that they became similar to healthy control neurons after 60 days of treatment. Tue, 23 Feb 2021 11:04:14 EST //www.koonmotors.com/releases/2021/02/210223110414.htm //www.koonmotors.com/releases/2021/01/210119114344.htm The secrets long hidden in the DNA of patients with amyotrophic lateral sclerosis (ALS) living in Malta have been unlocked, according to a new study. Tue, 19 Jan 2021 11:43:44 EST //www.koonmotors.com/releases/2021/01/210119114344.htm //www.koonmotors.com/releases/2020/12/201209115151.htm A research team has developed a diagnostic tool for the rare neurological disease amyotrophic lateral sclerosis (ALS). The study used the patented immuno-infrared sensor to analyze folding changes of proteins in the cerebrospinal fluid (CSF) of ALS patients after specific binding. Wed, 09 Dec 2020 11:51:51 EST //www.koonmotors.com/releases/2020/12/201209115151.htm //www.koonmotors.com/releases/2020/10/201016112859.htm An experimental medication that was recently shown to slow the progression of amyotrophic lateral sclerosis has now demonstrated the potential to also prolong patient survival. The findings come from a recent clinical trial. Fri, 16 Oct 2020 11:28:59 EDT //www.koonmotors.com/releases/2020/10/201016112859.htm //www.koonmotors.com/releases/2020/09/200923124628.htm Researchers have discovered a function for the protein missing in many types of ALS and FTLD, two neurodegenerative diseases. In neurons, the protein TDP-43 bound to messenger RNA that codes for pieces of ribosomes, the structures where proteins are made. Further tests showed that this allowed the RNA to be transported down to the axons, where it could promote axon growth and extension. Wed, 23 Sep 2020 12:46:28 EDT //www.koonmotors.com/releases/2020/09/200923124628.htm //www.koonmotors.com/releases/2020/09/200908131036.htm An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study. Tue, 08 Sep 2020 13:10:36 EDT //www.koonmotors.com/releases/2020/09/200908131036.htm //www.koonmotors.com/releases/2020/09/200901125911.htm Scientists have taken a significant step forward in the search to find effective new drug candidates for the treatment of Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease. Tue, 01 Sep 2020 12:59:11 EDT //www.koonmotors.com/releases/2020/09/200901125911.htm //www.koonmotors.com/releases/2020/07/200708174306.htm 一项临床试验发现证据表明,其实imental drug tofersen lowers levels of a disease-causing protein in people with an inherited form of amyotrophic lateral sclerosis, or ALS, caused by mutations in the gene SOD1. Wed, 08 Jul 2020 17:43:06 EDT //www.koonmotors.com/releases/2020/07/200708174306.htm //www.koonmotors.com/releases/2020/06/200610160435.htm Researchers have identified how certain gene mutations cause amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The pathway identified by the researchers may also be responsible for a certain form of dementia related to ALS. The finding could offer potential new approaches for treating this devastating condition. Wed, 10 Jun 2020 16:04:35 EDT //www.koonmotors.com/releases/2020/06/200610160435.htm //www.koonmotors.com/releases/2020/06/200601134547.htm Amyotrophic lateral sclerosis (ALS) is one of the most devastating adult-onset neurodegenerative diseases. Patients, including the late actor/playwright Sam Shepard, become progressively weaker and eventually paralyzed as their motor neurons degenerate and die. Mon, 01 Jun 2020 13:45:47 EDT //www.koonmotors.com/releases/2020/06/200601134547.htm //www.koonmotors.com/releases/2020/05/200528160517.htm A new study finds that restoring the protein SV2 in a genetic form of ALS can correct abnormalities in transmission and even prevent cells from dying, providing a new target for future therapies. Thu, 28 May 2020 16:05:17 EDT //www.koonmotors.com/releases/2020/05/200528160517.htm //www.koonmotors.com/releases/2020/03/200330122411.htm Scientists have provided new insights into how mutations in a gene called TBK1 cause amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that robs patients of movement, speech and ultimately, their lives. The researchers found that ALS-associated mutations in TBK1 can have both positive and negative effects on the progression of disease in mice genetically modified to have ALS-like symptoms. Mon, 30 Mar 2020 12:24:11 EDT //www.koonmotors.com/releases/2020/03/200330122411.htm //www.koonmotors.com/releases/2020/02/200226130523.htm With a new CRISPR gene-editing methodology, scientists have inactivated one of the genes responsible for an inherited form of amyotrophic lateral sclerosis -- a debilitating and fatal neurological disease for which there is no cure. The novel treatment slowed disease progression, improved muscle function and extended lifespan in mice with an aggressive form of ALS. Wed, 26 Feb 2020 13:05:23 EST //www.koonmotors.com/releases/2020/02/200226130523.htm //www.koonmotors.com/releases/2020/02/200224102022.htm The addition of dietary L-serine, a naturally occurring amino acid necessary for formation of proteins and nerve cells, delayed signs of amyotrophic lateral sclerosis (ALS) in an animal study. Mon, 24 Feb 2020 10:20:22 EST //www.koonmotors.com/releases/2020/02/200224102022.htm //www.koonmotors.com/releases/2020/02/200211121504.htm Disease-prompting bundles of proteins found within cells are cleared by unexpected processes. That knowledge could lead to ALS therapeutic solutions. Tue, 11 Feb 2020 12:15:04 EST //www.koonmotors.com/releases/2020/02/200211121504.htm //www.koonmotors.com/releases/2020/02/200204163646.htm 研究人员描述家庭nonin的好处vasive ventilation therapy, which includes a type referred to as bilevel positive airway pressure, or BiPAP -- for many patients with chronic obstructive pulmonary disease (COPD). The team identified a number of benefits, including reduced mortality, fewer hospital admissions, lower risk of intubation, improved shortness of breath, and fewer emergency department visits. Tue, 04 Feb 2020 16:36:46 EST //www.koonmotors.com/releases/2020/02/200204163646.htm //www.koonmotors.com/releases/2020/01/200108160316.htm Mitochondrial damage is increasingly recognized as a key factor underlying neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. A new screening platform has identified a set of drug-like compounds that may protect them. Wed, 08 Jan 2020 16:03:16 EST //www.koonmotors.com/releases/2020/01/200108160316.htm //www.koonmotors.com/releases/2019/12/191227085239.htm Novel spinal therapy/delivery approach prevented disease onset in neurodegenerative ALS disease model in adult mice and blocked progression in animals already showing disease symptoms. Fri, 27 Dec 2019 08:52:39 EST //www.koonmotors.com/releases/2019/12/191227085239.htm //www.koonmotors.com/releases/2019/11/191126100721.htm Korean research team made up of Dr. Hyung-Jun Kim and Shinrye Lee of KBRI, and professor Kiyoung Kim of Soonchunhyang University, found a new molecular mechanism of suppressing neuronal toxicity associateded dementia and Lou Gehrig's disease. Tue, 26 Nov 2019 10:07:21 EST //www.koonmotors.com/releases/2019/11/191126100721.htm //www.koonmotors.com/releases/2019/11/191107084038.htm Scientists have discovered a new phenomenon in the brain that could explain the development of early stages of neurodegeneration that is seen in diseases such as ALS, which affects voluntary muscle movement such as walking and talking. The discovery was so novel, the scientists needed to coin a new term to describe it: mitoautophagy, a collection of self-destructive mitochondria in diseased upper motor neurons of the brain that begin to disintegrate from within at a very early age. Thu, 07 Nov 2019 08:40:38 EST //www.koonmotors.com/releases/2019/11/191107084038.htm //www.koonmotors.com/releases/2019/10/191030101139.htm In neurodegenerative disease ALS, proteins called TDP-43 aggregate in patient tissues. A team led by researchers at Cold Spring Harbor Laboratory found that in ALS, TDP-43 proteins are dysfunctional, causing de-silencing of retrotransposons or 'jumping genes.' Wed, 30 Oct 2019 10:11:39 EDT //www.koonmotors.com/releases/2019/10/191030101139.htm //www.koonmotors.com/releases/2019/09/190923082238.htm Researchers have used a technique called high-throughput mutagenesis to study Amyotrophic Lateral Sclerosis (ALS), with unexpected results. Results showed that aggregation of TDP-43 is not harmful but actually protects cells, changing our understanding of ALS and opening the door to radically new therapeutic approaches. Mon, 23 Sep 2019 08:22:38 EDT //www.koonmotors.com/releases/2019/09/190923082238.htm //www.koonmotors.com/releases/2019/09/190917115449.htm A computer generated-simulation allowed researchers to see how a toxin produced by algal blooms in saltwater might cause Amyotrophic Lateral Sclerosis (ALS). Tue, 17 Sep 2019 11:54:49 EDT //www.koonmotors.com/releases/2019/09/190917115449.htm //www.koonmotors.com/releases/2019/09/190904125327.htm Researchers have made an important advance toward understanding why certain cells in the nervous system are prone to breaking down and dying, which is what happens in patients with ALS and other neurodegenerative disorders. Wed, 04 Sep 2019 12:53:27 EDT //www.koonmotors.com/releases/2019/09/190904125327.htm //www.koonmotors.com/releases/2019/08/190812130902.htm A robotic brace that supports the neck during its natural motion is the first device shown to dramatically assist ALS patients in holding their heads and actively supporting them during range of motion. The brace should improve patients' quality of life, not only in improving eye contact during conversation, but also in facilitating the use of eyes as a joystick to control movements on a computer, much as scientist Stephen Hawkins did. Mon, 12 Aug 2019 13:09:02 EDT //www.koonmotors.com/releases/2019/08/190812130902.htm //www.koonmotors.com/releases/2019/07/190722111923.htm New research in mice shows that the gut microbiome may affect the course of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Mon, 22 Jul 2019 11:19:23 EDT //www.koonmotors.com/releases/2019/07/190722111923.htm //www.koonmotors.com/releases/2019/07/190701144546.htm 领导的研究小组尼古拉•法,一个屁股ociate professor in the Department of Molecular Pharmacology, Physiology and Biotechnology at Brown University, used a combination of techniques to determine the atomic interactions that stabilize the liquid, yet 'condensed' phase of FUS, which is found in a a 'solid' or aggregate phase in some people with severe cases of amyotrophic lateral sclerosis (ALS) and a type of dementia called frontotemporal dementia. Mon, 01 Jul 2019 14:45:46 EDT //www.koonmotors.com/releases/2019/07/190701144546.htm //www.koonmotors.com/releases/2019/07/190701144537.htm Researchers identified chemical compounds that prevent stress-induced clumping of TDP-43 protein in ALS motor neurons grown in the lab -- a starting point for new ALS therapeutics. Mon, 01 Jul 2019 14:45:37 EDT //www.koonmotors.com/releases/2019/07/190701144537.htm //www.koonmotors.com/releases/2019/05/190524094313.htm New research on amyotrophic lateral sclerosis (AML) has revealed that a protein called membralin plays a key role in the disease process. The study suggests that membralin-boosting gene therapy is a potential therapeutic direction to treat this often deadly disease. Fri, 24 May 2019 09:43:13 EDT //www.koonmotors.com/releases/2019/05/190524094313.htm //www.koonmotors.com/releases/2019/05/190509112251.htm Researchers have developed a stem cell based model in order to study the resilience and vulnerability of neurons in the neurodegenerative disease ALS. The results can aid in the identification of new genetic targets for treatments protecting sensitive neurons. Thu, 09 May 2019 11:22:51 EDT //www.koonmotors.com/releases/2019/05/190509112251.htm //www.koonmotors.com/releases/2019/05/190501161224.htm An early stage trial of an investigational therapy for amyotrophic lateral sclerosis (ALS) suggests that people could tolerate the experimental drug and, in exploratory results, the experimental drug was linked to possible slower progression in people with a genetic form of the disease caused by mutations in a gene called superoxide dismutase 1 (SOD1). Wed, 01 May 2019 16:12:24 EDT //www.koonmotors.com/releases/2019/05/190501161224.htm //www.koonmotors.com/releases/2019/04/190424153558.htm A state-of-the-art brain-machine interface created by neuroscientists can generate natural-sounding synthetic speech by using brain activity to control a virtual vocal tract -- an anatomically detailed computer simulation including the lips, jaw, tongue, and larynx. The study was conducted in research participants with intact speech, but the technology could one day restore the voices of people who have lost the ability to speak due to paralysis or neurological damage. Wed, 24 Apr 2019 15:35:58 EDT //www.koonmotors.com/releases/2019/04/190424153558.htm